Last reviewed · How we verify
MnSOD Mimetic BMX-001 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
MnSOD Mimetic BMX-001 (MnSOD Mimetic BMX-001) — NRG Oncology.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MnSOD Mimetic BMX-001 TARGET | MnSOD Mimetic BMX-001 | NRG Oncology | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- MnSOD Mimetic BMX-001 CI watch — RSS
- MnSOD Mimetic BMX-001 CI watch — Atom
- MnSOD Mimetic BMX-001 CI watch — JSON
- MnSOD Mimetic BMX-001 alone — RSS
Cite this brief
Drug Landscape (2026). MnSOD Mimetic BMX-001 — Competitive Intelligence Brief. https://druglandscape.com/ci/mnsod-mimetic-bmx-001. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab